NCT00861458View on ClinicalTrials.gov

Bioavailability Study Of PF-00868554 Administered As 3x250mg Oral Tablets (Wet Granulate, 3x250mg Oral Tablets (Dry Granulate) And 750mg Solution Under Fed State

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

April 30, 2009

Primary Completion Date

June 30, 2009

Study Completion Date

June 30, 2009

Conditions
Hepatitis C Virus
Interventions
DRUG

Pharmacokinetics

Single dose of 750 mg PF-00868554 as a solution and tablets.

Trial Locations (1)

1070

Pfizer Investigational Site, Brussels

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY